<DOC>
	<DOCNO>NCT00245895</DOCNO>
	<brief_summary>The purpose study see darbepoetin alfa effective treatment anemia prostate cancer patient , , dose effective . Sometimes prostate cancer patient low red blood cell count ( low hemoglobin ) various treatment receive , chemotherapy . The red blood cell deliver oxygen tissue . This help give patient energy .</brief_summary>
	<brief_title>Study Aranesp Treat Anemia Prostate Cancer Patients .</brief_title>
	<detailed_description>This study evaluate effectiveness Darbepoetin alfa , ( also refer Aranesp NESP ) , assess dose NESP require treat anemia prostate cancer patient , side effect NESP , whether NESP affect patient ' quality life . NESP approve FDA treatment anemia patient chronic kidney failure treatment anemia cancer patient receive chemotherapy . It consider experimental treatment anemia prostate cancer patient .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Patients must either histologically confirm adenocarcinoma prostate clinical evidence include PSA great 50 , evidence bone metastasis , currently receive either androgen suppression chemotherapy . Patients concurrent androgen deprivation treatment consist either orchiectomy GnRH agonist ( Zoladex Lupron ) without androgen receptor antagonist ( Casodex , Nilandron , Eulexin ) therapy , long therapy initiate within last 3 month . Finasteride treatment must discontinue . Secondary hormonal therapy DES ketoconazole permit . Patients may history radiation therapy , provide least 6 week elapse last treatment date study day 1 . Patients must life expectancy least 12 month zubrod performance status 02 . Patients must evidence hemolysis , overt gastrointestinal bleeding bleeding due recent surgery . Patients must serum creatinine level less equal 2 mg/dL . Patients must adequate liver function , evidence aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less equal 2 x ULN within 3 month prior screen . Before studyspecific procedure , patient must give write informed consent participate study . Patients present active primary metastatic malignancy involve CNS . Patients previous history primary metastatic malignancy involve CNS eligible study , clinical sign symptom , treatment CNS disease , history seizure within previous 2 year . Patients receive rHuEPO therapy within 4 week prior first dose study drug . Active bleeding RBC transfusion within 4 week prior fist dose study drug . Patients active seizure disorder . Patients previous history seizure disorder eligible study , evidence seizure activity , free anticonvulsant medication previous 5 year . Patients uncontrolled angina , congestive heart failure uncontrolled cardiac arrhythmia . Patients uncontrolled hypertension Patients history hyperviscosity syndrome Patients evidence clinically significant systemic active infection inflammatory disease Patients know positive test human immunodeficiency virus ( HIV ) infection Patients inadequate iron store ( Fe/TIBC less 15 % ferritin le 10.0 mg/L ) Patients history primary hematologic disorder could cause anemia Patients currently receive , yet 30 day past receiving ( prior first dose study drug ) , investigational agent device approve indication govern regulatory authority . Note : exception make patient receive DN101 , new formulation calcitriol , investigational study . Patients previously receive Aranesp ( darbepoetin alfa ) within 4 week prior fist dose study drug . Patients know hypersensitivity active substance excipients .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Anemia ,</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>